Accelerate the drug development process by identifying immunogenic peptides, such as neo-antigens and viral antigens, at an early stage. This enables the selection of compounds that can trigger desired immune responses. Having an understanding of a biotherapeutic's immunogenic profile facilitates the establishment of a robust R&D strategy, ensuring a seamless transition to the next stages of the drug development process.
Gain a thorough understanding of a biotherapeutic's immunogenic epitopes to enhance its effectiveness and safety.
ImmuneSpec's innovative approach combines comprehensive immunogenic analysis with expert knowledge to provide a unique solution for optimizing biotherapeutics. Our advanced MAPPS report includes detailed information about specific immunogenic areas, allowing biotherapeutic optimization with minimal modifications.
Utilize ImmuneSpec's advanced platform to gain a better understanding of the immunogenicity of your biotherapeutic. This facilitates the evaluation of its safety and efficacy, leading to faster identification of potential adverse effects.
Our data supports the demonstration of safety and efficacy of biotherapeutic candidates to regulatory authorities and investors, ensuring market access and securing funding for further developments.
Institute of Tropical Medicine Antwerp
An advanced drug development process.
The benefits of immunogenic profiling.
The identification of a compound's immunogenic areas shows beneficial effects at different stages of the drug development process.